148 related articles for article (PubMed ID: 20005712)
1. Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.
Nishizawa R; Nishiyama T; Hisaichi K; Hirai K; Habashita H; Takaoka Y; Tada H; Sagawa K; Shibayama S; Maeda K; Mitsuya H; Nakai H; Fukushima D; Toda M
Bioorg Med Chem Lett; 2010 Jan; 20(2):763-6. PubMed ID: 20005712
[TBL] [Abstract][Full Text] [Related]
2. Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Nishizawa R; Nishiyama T; Hisaichi K; Minamoto C; Matsunaga N; Takaoka Y; Nakai H; Jenkinson S; Kazmierski WM; Tada H; Sagawa K; Shibayama S; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2011 Feb; 21(4):1141-5. PubMed ID: 21256008
[TBL] [Abstract][Full Text] [Related]
3. Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Nishizawa R; Nishiyama T; Hisaichi K; Hirai K; Habashita H; Takaoka Y; Tada H; Sagawa K; Shibayama S; Maeda K; Mitsuya H; Nakai H; Fukushima D; Toda M
Bioorg Med Chem; 2010 Jul; 18(14):5208-23. PubMed ID: 20542438
[TBL] [Abstract][Full Text] [Related]
4. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
Tagat JR; Steensma RW; McCombie SW; Nazareno DV; Lin SI; Neustadt BR; Cox K; Xu S; Wojcik L; Murray MG; Vantuno N; Baroudy BM; Strizki JM
J Med Chem; 2001 Oct; 44(21):3343-6. PubMed ID: 11585438
[TBL] [Abstract][Full Text] [Related]
5. Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.
Rotstein DM; Melville CR; Padilla F; Cournoyer D; Lee EK; Lemoine R; Petersen AC; Setti LQ; Wanner J; Chen L; Filonova L; Loughhead DG; Manka J; Lin XF; Gleason S; Sankuratri S; Ji C; Derosier A; Dioszegi M; Heilek G; Jekle A; Berry P; Mau CI; Weller P
Bioorg Med Chem Lett; 2010 May; 20(10):3116-9. PubMed ID: 20417098
[TBL] [Abstract][Full Text] [Related]
6. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
McCombie SW; Tagat JR; Vice SF; Lin SI; Steensma R; Palani A; Neustadt BR; Baroudy BM; Strizki JM; Endres M; Cox K; Dan N; Chou CC
Bioorg Med Chem Lett; 2003 Feb; 13(3):567-71. PubMed ID: 12565973
[TBL] [Abstract][Full Text] [Related]
7. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Nishizawa R; Nishiyama T; Hisaichi K; Minamoto C; Murota M; Takaoka Y; Nakai H; Tada H; Sagawa K; Shibayama S; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem; 2011 Jul; 19(13):4028-42. PubMed ID: 21658961
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
Palani A; Shapiro S; Clader JW; Greenlee WJ; Cox K; Strizki J; Endres M; Baroudy BM
J Med Chem; 2001 Oct; 44(21):3339-42. PubMed ID: 11585437
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.
Liu T; Weng Z; Dong X; Chen L; Ma L; Cen S; Zhou N; Hu Y
PLoS One; 2013; 8(1):e53636. PubMed ID: 23308267
[TBL] [Abstract][Full Text] [Related]
12. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
[TBL] [Abstract][Full Text] [Related]
13. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Nishizawa R; Nishiyama T; Hisaichi K; Matsunaga N; Minamoto C; Habashita H; Takaoka Y; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2007 Feb; 17(3):727-31. PubMed ID: 17118654
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
Hu S; Wang Z; Hou T; Ma X; Li J; Liu T; Xie X; Hu Y
Bioorg Med Chem; 2015 Mar; 23(5):1157-68. PubMed ID: 25638498
[TBL] [Abstract][Full Text] [Related]
15. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element.
Tagat JR; McCombie SW; Steensma RW; Lin S; Nazareno DV; Baroudy B; Vantuno N; Xu S; Liu J
Bioorg Med Chem Lett; 2001 Aug; 11(16):2143-6. PubMed ID: 11514156
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): modification of the acyl portion.
Duan M; Peckham J; Edelstein M; Ferris R; Kazmierski WM; Spaltenstein A; Wheelan P; Xiong Z
Bioorg Med Chem Lett; 2010 Dec; 20(24):7401-4. PubMed ID: 21055933
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
Peng P; Chen H; Zhu Y; Wang Z; Li J; Luo RH; Wang J; Chen L; Yang LM; Jiang H; Xie X; Wu B; Zheng YT; Liu H
J Med Chem; 2018 Nov; 61(21):9621-9636. PubMed ID: 30234300
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion.
Duan M; Peckham J; Edelstein M; Ferris R; Kazmierski WM; Spaltenstein A; Wheelan P; Xiong Z
Bioorg Med Chem Lett; 2010 Dec; 20(24):7397-400. PubMed ID: 21035337
[TBL] [Abstract][Full Text] [Related]
19. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.
Hale JJ; Budhu RJ; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano SJ; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini EA
Bioorg Med Chem Lett; 2002 Oct; 12(20):2997-3000. PubMed ID: 12270192
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors.
Kazmierski W; Bifulco N; Yang H; Boone L; DeAnda F; Watson C; Kenakin T
Bioorg Med Chem; 2003 Jul; 11(13):2663-76. PubMed ID: 12788340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
